GL1X · GenesisL1 explorer

MolNFT v1 · #186387 · protein

Crystal structure of human TLR8 ectodomain bound to small molecule antagonist 21

7RC9 · Toll-like receptor 8: “Crystal structure of human TLR8 ectodomain bound to small molecule antagonist 21”. X-ray diffraction, 4 ligands (RQY, NAG, MAN), 11 pockets (best druggability 0.79). MolNFT v1 #186387 on GenesisL1: 3D…

PDB
7RC9
Type
protein
Length
1,474 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Toll-like receptor 8
UniProt
Q9NR97
Ligands
RQY, NAG, MAN, BMA
Pockets
11 · best druggability 0.79

Structure

x-ray diffraction · 1 distinct chain · 11% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BToll-like receptor 8protein73711% helix, 15% strandQ9NR97

Ligands and binding sites

  • RQY · 2-(2,6-dimethylpyridin-4-yl)-5-(piperidin-4-yl)-3-(propan-2-yl)-1H-indole · ligand · 2 copies · chains A, B
  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 26 copies · chains A, B
  • MAN · alpha-D-mannopyranose · sugar · 7 copies · chains B
  • BMA · beta-D-mannopyranose · sugar · 6 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

11 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110610.790.80111RQY
22230.610.8129NAG
32240.600.8031NAG
4670.500.8519empty
52400.490.7439empty

Interfaces

1 interface between chains.

  • A–B · 1319 Ų buried · 10 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 20 glycan, 12 disulfide (N-glycosylation, disulfide).

Compared structures

  • 7RC9 · Crystal structure of human TLR8 ectodomain bound to small molecule antagonist 21 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.